Document is current
Any future updates will be listed below
-
Authors
Škorvagová, A. https://orcid.org/0009-0004-3390-8530
Ribaldi, F. https://orcid.org/0000-0001-9208-4472
Cerman, J. https://orcid.org/0000-0003-1135-6865
Wang, C. https://orcid.org/0009-0009-5914-5398
Scheffler, M. https://orcid.org/0000-0003-2274-5129
Mendes, A. J https://orcid.org/0000-0002-9497-0707
Wyss-Dominguez, C. https://orcid.org/0009-0009-2982-0188
Garibotto, V. https://orcid.org/0000-0003-2422-698X
Frisoni, G. https://orcid.org/0000-0001-7075-7082
Andel, R. https://orcid.org/0000-0003-4083-4790
Boccalini, C. https://orcid.org/0000-0002-3518-436X
-
Funding
Funding for this research was provided by:
Charles University
- License Information
-
More Information
Article History
Received: 14 August 2025
Accepted: 18 November 2025
First Online: 2 March 2026
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines. Approval was granted by the Cantonal Commission for Research Ethics (CCER) of Geneva, Switzerland (Reference numbers: 2020–00403 and PB_2016–01346).
: Written informed consent was obtained from all participants or their legally authorized representatives.
: The authors affirm that human research participants provided informed consent for the publication of anonymized data included in this article.
: VG received research support and speaker fees through her institution from GE Healthcare, Siemens Healthineers, Novo Nordisk, Janssen and Novartis.GBF has received unrestricted grants and support for event organization from Roche Pharmaceuticals; OM Pharma; Eisai Pharmaceuticals; Vifor Pharma; Biogen Pharmaceuticals; Novo Nordisk; GE Healthcare; Eli Lilly.
